Literature DB >> 22930295

Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study.

S Shoptaw1, R Stall, J Bordon, U Kao, C Cox, X Li, D G Ostrow, M W Plankey.   

Abstract

We examined associations between stimulant use (methamphetamine and cocaine) and other substances (nicotine, marijuana, alcohol and inhaled nitrites) with immune function biomarkers among HIV-seropositive (HIV +) men taking highly active antiretroviral therapy (ART) and HIV-seronegative (HIV-) men in the Multicenter AIDS Cohort Study. Among HIV + men, cumulative adherence to ART (4.07, 95% confidence interval [CI]: 3.52, 4.71, per 10 years of adherent ART use), and recent cohort enrolment (1.38; 95% CI: 1.24, 1.55) were multiplicatively associated with increase in CD4+/CD8+ ratios. Cumulative use of methamphetamine (0.93; 95% CI: 0.88, 0.98, per 10 use-years), cocaine (0.93; 95% CI: 0.89, 0.96, per 10 use-years) and cumulative medical visits (0.99; 95% CI: 0.98, 0.99, per 10 visit-years), each showed small negative associations with CD4+/CD8+ ratios. Among HIV- men, cumulative medical visits (0.996; 95% CI: 0.993, 0.999), cumulative number of male sexual partners (0.999; 95% CI: 0.998, 0.9998, per 10 partner-years) and cigarette pack-years (1.10; 95% CI: 1.02, 1.18, per 10 pack-years) were associated with CD4+/CD8+ ratios over the same period. ART adherence is associated with a positive immune function independent of stimulant use, underscoring the influence of ART on immune health for HIV+ men who engage in stimulant use.

Entities:  

Mesh:

Year:  2012        PMID: 22930295      PMCID: PMC3576843          DOI: 10.1258/ijsa.2012.011322

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  20 in total

1.  Adding fuel to the fire: methamphetamine enhances HIV infection.

Authors:  Raghava Potula; Yuri Persidsky
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

2.  Cofactors for HIV disease progression in a cohort of homosexual and bisexual men.

Authors:  E Vittinghoff; N A Hessol; P Bacchetti; R E Fusaro; S D Holmberg; S P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

3.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

4.  Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.

Authors:  Donna Mildvan; John Spritzler; Sidney E Grossberg; John L Fahey; David M Johnston; Barbara R Schock; Jonathan Kagan
Journal:  Clin Infect Dis       Date:  2005-02-18       Impact factor: 9.079

5.  Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes.

Authors:  Michael D Roth; Donald P Tashkin; Ruth Choi; Beth D Jamieson; Jerome A Zack; Gayle Cocita Baldwin
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

6.  Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study.

Authors:  Joseph G Feldman; Howard Minkoff; Michael F Schneider; Stephen J Gange; Mardge Cohen; D Heather Watts; Monica Gandhi; Robert S Mocharnuk; Kathryn Anastos
Journal:  Am J Public Health       Date:  2006-05-02       Impact factor: 9.308

7.  Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.

Authors:  Marianna K Baum; Carlin Rafie; Shenghan Lai; Sabrina Sales; Bryan Page; Adriana Campa
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.

Authors:  Judith A Cook; Jane K Burke-Miller; Mardge H Cohen; Robert L Cook; David Vlahov; Tracey E Wilson; Elizabeth T Golub; Rebecca M Schwartz; Andrea A Howard; Claudia Ponath; Michael W Plankey; Alexandra M Levine; Andrea Levine; Dennis D Grey
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

9.  Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy.

Authors:  Adam W Carrico; Mallory O Johnson; Stephen F Morin; Robert H Remien; Elise D Riley; Frederick M Hecht; Dietmar Fuchs
Journal:  Brain Behav Immun       Date:  2008-08-03       Impact factor: 7.217

10.  Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men.

Authors:  Chun Chao; Lisa P Jacobson; Donald Tashkin; Otoniel Martínez-Maza; Michael D Roth; Joseph B Margolick; Joan S Chmiel; Charles Rinaldo; Zuo-Feng Zhang; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2008-01-03       Impact factor: 4.492

View more
  26 in total

1.  Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study.

Authors:  M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

2.  Prevalence and correlates of marijuana use among HIV-seropositive and seronegative men in the Multicenter AIDS Cohort Study (MACS), 1984-2013.

Authors:  Chukwuemeka N Okafor; Robert L Cook; Xinguang Chen; Pamela J Surkan; James T Becker; Steve Shoptaw; Eileen Martin; Michael W Plankey
Journal:  Am J Drug Alcohol Abuse       Date:  2016-11-03       Impact factor: 3.829

3.  Association between alcohol consumption trajectories and clinical profiles among women and men living with HIV.

Authors:  Natalie E Kelso-Chichetto; Michael Plankey; Alison G Abraham; Nicole Ennis; Xinguang Chen; Robert Bolan; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2017-06-16       Impact factor: 3.829

Review 4.  The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis.

Authors:  Ryan Colby Passaro; Jui Pandhare; Han-Zhu Qian; Chandravanu Dash
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-08       Impact factor: 4.147

5.  HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection.

Authors:  Derek K Ng; Lisa P Jacobson; Todd T Brown; Frank J Palella; Jeremy J Martinson; Robert Bolan; Edgar R Miller; George J Schwartz; Alison G Abraham; Michelle M Estrella
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

6.  Depression and sexual dysfunction among HIV-positive and HIV-negative men who have sex with men: mediation by use of antidepressants and recreational stimulants.

Authors:  Trevor A Hart; Brian Mustanski; Daniel T Ryan; Pamina M Gorbach; Ron D Stall; Pamela J Surkan; Michael Plankey
Journal:  Arch Sex Behav       Date:  2014-03-27

Review 7.  Role of Autophagy in HIV Pathogenesis and Drug Abuse.

Authors:  Lu Cao; Alexey Glazyrin; Santosh Kumar; Anil Kumar
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  Association of Marijuana Use with Changes in Cognitive Processing Speed and Flexibility for 17 Years in HIV-Seropositive and HIV-Seronegative Men.

Authors:  Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook
Journal:  Subst Use Misuse       Date:  2019-01-30       Impact factor: 2.164

9.  Someone to count on: social support as an effect modifier of viral load suppression in a prospective cohort study.

Authors:  M Reuel Friedman; Robert W S Coulter; Anthony J Silvestre; Ron Stall; Linda Teplin; Steve Shoptaw; Pamela J Surkan; Michael W Plankey
Journal:  AIDS Care       Date:  2016-07-25

Review 10.  An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research.

Authors:  Lisa R Norman; Michael Basso
Journal:  Curr Drug Abuse Rev       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.